Literature DB >> 27510248

Higher cost of implementing Xpert(®) MTB/RIF in Ugandan peripheral settings: implications for cost-effectiveness.

E Hsiang1, K M Little2, P Haguma3, C F Hanrahan4, A Katamba3, A Cattamanchi5, J L Davis6, A Vassall7, D Dowdy4.   

Abstract

SETTING: Initial cost-effectiveness evaluations of Xpert(®) MTB/RIF for tuberculosis (TB) diagnosis have not fully accounted for the realities of implementation in peripheral settings.
OBJECTIVE: To evaluate costs and diagnostic outcomes of Xpert testing implemented at various health care levels in Uganda.
DESIGN: We collected empirical cost data from five health centers utilizing Xpert for TB diagnosis, using an ingredients approach. We reviewed laboratory and patient records to assess outcomes at these sites and10 sites without Xpert. We also estimated incremental cost-effectiveness of Xpert testing; our primary outcome was the incremental cost of Xpert testing per newly detected TB case.
RESULTS: The mean unit cost of an Xpert test was US$21 based on a mean monthly volume of 54 tests per site, although unit cost varied widely (US$16-58) and was primarily determined by testing volume. Total diagnostic costs were 2.4-fold higher in Xpert clinics than in non-Xpert clinics; however, Xpert only increased diagnoses by 12%. The diagnostic costs of Xpert averaged US$119 per newly detected TB case, but were as high as US$885 at the center with the lowest volume of tests.
CONCLUSION: Xpert testing can detect TB cases at reasonable cost, but may double diagnostic budgets for relatively small gains, with cost-effectiveness deteriorating with lower testing volumes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27510248      PMCID: PMC5018405          DOI: 10.5588/ijtld.16.0200

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  24 in total

1.  Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy.

Authors:  Taiwo O Abimbola; Barbara J Marston; Anand A Date; John M Blandford; Nalinee Sangrujee; Stefan Z Wiktor
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

2.  The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.

Authors:  Jason R Andrews; Stephen D Lawn; Corina Rusu; Robin Wood; Farzad Noubary; Melissa A Bender; C Robert Horsburgh; Elena Losina; Kenneth A Freedberg; Rochelle P Walensky
Journal:  AIDS       Date:  2012-05-15       Impact factor: 4.177

Review 3.  Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects.

Authors:  Madhukar Pai; Marco Schito
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

4.  Xpert MTB/RIF for diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and affordability analysis.

Authors:  Andrea Pantoja; Christopher Fitzpatrick; Anna Vassall; Karin Weyer; Katherine Floyd
Journal:  Eur Respir J       Date:  2012-12-20       Impact factor: 16.671

5.  Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa.

Authors:  Kathryn Schnippel; Gesine Meyer-Rath; Lawrence Long; William MacLeod; Ian Sanne; Wendy S Stevens; Sydney Rosen
Journal:  Trop Med Int Health       Date:  2012-06-12       Impact factor: 2.622

6.  Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.

Authors:  Kuldeep Singh Sachdeva; Neeraj Raizada; Achuthan Sreenivas; Anna H Van't Hoog; Susan van den Hof; Puneet K Dewan; Rahul Thakur; R S Gupta; Shubhangi Kulsange; Bhavin Vadera; Ameet Babre; Christen Gray; Malik Parmar; Mayank Ghedia; Ranjani Ramachandran; Umesh Alavadi; Nimalan Arinaminpathy; Claudia Denkinger; Catharina Boehme; C N Paramasivan
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

7.  Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.

Authors:  Helen S Cox; Slindile Mbhele; Neisha Mohess; Andrew Whitelaw; Odelia Muller; Widaad Zemanay; Francesca Little; Virginia Azevedo; John Simpson; Catharina C Boehme; Mark P Nicol
Journal:  PLoS Med       Date:  2014-11-25       Impact factor: 11.069

8.  The importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission model.

Authors:  Henrik Salje; Jason R Andrews; Sarang Deo; Srinath Satyanarayana; Amanda Y Sun; Madhukar Pai; David W Dowdy
Journal:  PLoS Med       Date:  2014-07-15       Impact factor: 11.069

9.  Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial.

Authors:  Violet N Chihota; Sibuse Ginindza; Kerrigan McCarthy; Alison D Grant; Gavin Churchyard; Katherine Fielding
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

10.  The hidden costs of installing Xpert machines in a tuberculosis high-burden country: experiences from Nigeria.

Authors:  Saddiq Tsimiri Abdurrahman; Nnamdi Emenyonu; Olusegun Joshua Obasanya; Lovett Lawson; Russell Dacombe; Muhammad Muhammad; Olanrewaju Oladimeji; Luis Eduardo Cuevas
Journal:  Pan Afr Med J       Date:  2014-08-05
View more
  19 in total

Review 1.  Advances in technologies for cervical cancer detection in low-resource settings.

Authors:  Kathryn A Kundrod; Chelsey A Smith; Brady Hunt; Richard A Schwarz; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Expert Rev Mol Diagn       Date:  2019-08-01       Impact factor: 5.225

2.  Costs along the TB diagnostic pathway in Uganda.

Authors:  A Tucker; D Oyuku; T Nalugwa; M Nantale; O Ferguson; K Farr; T F Reza; P B Shete; A Cattamanchi; D W Dowdy; H Sohn; A Katamba
Journal:  Int J Tuberc Lung Dis       Date:  2021-01-01       Impact factor: 2.373

3.  Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis.

Authors:  Samuel G Schumacher; William A Wells; Mark P Nicol; Karen R Steingart; Grant Theron; Susan E Dorman; Madhukar Pai; Gavin Churchyard; Lesley Scott; Wendy Stevens; Pamela Nabeta; David Alland; Karin Weyer; Claudia M Denkinger; Christopher Gilpin
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

4.  Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.

Authors:  Anil Pooran; Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Lawrence Mwenge; Farirai Mutenherwa; Paul Lecesse; John Metcalfe; Hojoon Sohn; Michael Hoelscher; Alex Pym; Jonny Peter; David Dowdy; Keertan Dheda
Journal:  Lancet Glob Health       Date:  2019-06       Impact factor: 26.763

5.  Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach.

Authors:  Irene Ayakaka; Sara Ackerman; Joseph M Ggita; Phoebe Kajubi; David Dowdy; Jessica E Haberer; Elizabeth Fair; Philip Hopewell; Margaret A Handley; Adithya Cattamanchi; Achilles Katamba; J Lucian Davis
Journal:  Implement Sci       Date:  2017-03-09       Impact factor: 7.327

6.  Catalysing progressive uptake of newer diagnostics by health care providers through outreach and education in four major cities of India.

Authors:  Neeraj Raizada; Sunil D Khaparde; Soumya Swaminathan; Sanjay Sarin; Virender Singh Salhotra; Aakshi Kalra; Ashwani Khanna; K K Chopra; M Hanif; K R Umadevi; Syed Hissar; Sreenivas Achuthan Nair; C H Surya Prakash; B K Saha; Raghuram Rao; Claudia Denkinger; Catharina Boehme
Journal:  PLoS One       Date:  2018-03-06       Impact factor: 3.240

7.  Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.

Authors:  David J Lee; Nagalingeswaran Kumarasamy; Stephen C Resch; Gomathi N Sivaramakrishnan; Kenneth H Mayer; Srikanth Tripathy; A David Paltiel; Kenneth A Freedberg; Krishna P Reddy
Journal:  PLoS One       Date:  2019-07-02       Impact factor: 3.240

8.  Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda.

Authors:  Willy Ssengooba; Jean de Dieu Iragena; Kevin Komakech; Iginitius Okello; Joanitah Nalunjogi; Winceslaus Katagira; Ivan Kimuli; Susan Adakun; Moses L Joloba; Gabriela Torrea; Bruce J Kirenga
Journal:  Open Forum Infect Dis       Date:  2021-04-02       Impact factor: 3.835

9.  A yield and cost comparison of tuberculosis contact investigation and intensified case finding in Uganda.

Authors:  Michael Kakinda; Joseph K B Matovu
Journal:  PLoS One       Date:  2020-06-08       Impact factor: 3.240

10.  Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model.

Authors:  Hojoon Sohn; Parastu Kasaie; Emily Kendall; Gabriela B Gomez; Anna Vassall; Madhukar Pai; David Dowdy
Journal:  BMC Med       Date:  2019-08-06       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.